Calidi Biotherapeutics Presents New Data On CLD-401 Program That It Expects To Enter Clinic In Q1 Of 2027 And In Situ T-Cell Engager Program, At 2026 AACR D3 Conference

Loading news article.

Calidi Biotherapeutics Presents New Data On CLD-401 Program That It Expects To Enter Clinic In Q1 Of 2027 And In Situ T-Cell Engager Program, At 2026 AACR D3 Conference | WAPE

Calidi Biotherapeutics Presents New Data On CLD-401 Program That It Expects To Enter Clinic In Q1 Of 2027 And In Situ T-Cell Engager Program, At 2026 AACR D3 Conference

Article summary

Related companies

Comments —